Generic Semaglutide Pricing Could Disrupt Global Markets
Discover the potential of Generic Semaglutide Pricing, where new research shows significant savings on weight-loss medications.
FDA Biosimilar Development Guidance Targets Treatment Costs
Learn how the new FDA biosimilar development guidance can significantly lower biologic medicine costs and improve accessibility.
Eli Lilly 2026 Guidance Signals Momentum In Obesity Care
Eli Lilly has forecast 2026 profit and revenue above Wall Street expectations, reinforcing how fast the obesity market is reshaping Big Pharma growth plans. The recent Eli Lilly 2026 Guidance reflects the company’s confidence in strong future performance. The company also beat estimates for fourth-quarter earnings, helped by strong demand for its injectable weight-loss and…...
Generic Semaglutide Set to Disrupt Global GLP‑1 Market
Aspen Pharmacare is lining up a generic semaglutide launch in Canada, promising big discounts, and widening GLP-1 access.
1.4% SEP Increase Impacts Pharmaceutical Investment
Understanding the 1.4% SEP increase: why the pharmaceutical sector is urging a reconsideration of the price cap.
Pfizer Drug Pricing Deal Sees Stocks Soar
Learn about the Pfizer drug pricing deal that has stirred market reactions. Find out why analysts call it "more optics than bite".
Trump’s Tariff Stick Won’t Bring Generic Drug Manufacturing Home
Analyze the implications of Trump's Tariff Stick for the US generics industry. Tariffs might worsen the supply of critical medicines.
Are New Cancer Treatments Worth the Price?
Learn about the cost of cancer treatments and the reality behind their effectiveness. Are patients getting the care they deserve?
Trump targets drug costs in sweeping executive order
Trump targets drug costs with a new executive order to lower prescription prices to align with international rates.
Trump Drug Price Executive Order Targets Medicare Negotiations
Get insights on the Trump drug price executive order and how it may reshape timelines for drug price negotiations.